exenatide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
peptides and glycopeptides 1123 141758-74-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • exenatide
  • byetta
  • exenatide synthetic
  • bydureon
  • exendin-4
  • AC002993
  • AC2993A
A synthetic form of exendin-4, a 39-amino acid peptide isolated from the venom of the Gila monster lizard (Heloderma suspectum). Exenatide increases CYCLIC AMP levels in pancreatic acinar cells and acts as a GLUCAGON-LIKE PEPTIDE-1 RECEPTOR (GLP-1) agonist and incretin mimetic, enhancing insulin secretion in response to increased glucose levels; it also suppresses inappropriate glucagon secretion and slows gastric emptying. It is used an anti-diabetic and anti-obesity agent.
  • Molecular weight: 4186.63
  • Formula: C184H282N50O60S
  • CLOGP:
  • LIPINSKI: None
  • HAC: 110
  • HDO: 58
  • TPSA: 1749.75
  • ALOGS:
  • ROTB: 134

Drug dosage:

DoseUnitRoute
0.29 mg P
15 mcg P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 25 mg/mL Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.00 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
April 28, 2005 FDA ASTRAZENECA AB

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Blood glucose increased 1999.42 17.32 789 22174 94457 90511027
Pancreatitis 1973.23 17.32 719 22244 69107 90536377
Weight decreased 1134.68 17.32 861 22102 379049 90226435
Injection site nodule 734.03 17.32 180 22783 4293 90601191
Nausea 596.56 17.32 1027 21936 1109289 89496195
Blood glucose decreased 596.22 17.32 224 22739 23205 90582279
Pancreatitis acute 404.88 17.32 186 22777 31929 90573555
Injection site haemorrhage 360.05 17.32 165 22798 28153 90577331
Glycosylated haemoglobin increased 332.22 17.32 131 22832 15431 90590053
Injection site pruritus 303.82 17.32 182 22781 53652 90551832
Injection site mass 300.67 17.32 135 22828 21955 90583529
Incorrect dose administered by device 270.61 17.32 87 22876 5650 90599834
Device leakage 270.38 17.32 100 22863 9891 90595593
Injection site extravasation 261.58 17.32 95 22868 8924 90596560
Hypoglycaemia 226.03 17.32 167 22796 69681 90535803
Injection site pain 225.71 17.32 248 22715 173451 90432033
Injection site urticaria 213.47 17.32 100 22863 17911 90587573
Wrong technique in device usage process 205.47 17.32 71 22892 5764 90599720
Vomiting 202.40 17.32 543 22420 787750 89817734
Blood glucose abnormal 178.66 17.32 73 22890 9419 90596065
Pancreatic carcinoma 176.94 17.32 70 22893 8307 90597177
Device malfunction 172.94 17.32 91 22872 20886 90584598
Injection site erythema 168.25 17.32 163 22800 98339 90507145
Injection site bruising 166.79 17.32 124 22839 52183 90553301
Injection site rash 163.55 17.32 92 22871 24081 90581403
Decreased appetite 162.55 17.32 319 22644 376221 90229263
Device delivery system issue 158.08 17.32 44 22919 1734 90603750
Lipase increased 135.70 17.32 63 22900 11048 90594436
Incorrect dose administered 128.01 17.32 127 22836 78803 90526681
Blood glucose fluctuation 127.01 17.32 48 22915 5035 90600449
Injection site irritation 119.16 17.32 48 22915 5967 90599517
Diabetic ketoacidosis 118.45 17.32 75 22888 24332 90581152
Pancreatitis chronic 113.44 17.32 38 22925 2805 90602679
Diabetes mellitus inadequate control 112.72 17.32 66 22897 18618 90586866
Cholelithiasis 111.16 17.32 98 22865 52408 90553076
Device use issue 107.23 17.32 39 22924 3674 90601810
Early satiety 103.35 17.32 30 22933 1377 90604107
Intentional device misuse 98.26 17.32 26 22937 844 90604640
Hyperglycaemia 91.99 17.32 87 22876 50883 90554601
Pancreatic carcinoma metastatic 87.73 17.32 30 22933 2358 90603126
Device issue 80.91 17.32 64 22899 29473 90576011
Needle issue 80.84 17.32 48 22915 13886 90591598
Injury associated with device 79.47 17.32 33 22930 4431 90601053
Acute kidney injury 78.94 17.32 218 22745 320169 90285315
Systemic lupus erythematosus 75.34 17.32 4 22959 361892 90243592
Lactic acidosis 74.13 17.32 77 22886 50386 90555098
Joint swelling 70.73 17.32 20 22943 503280 90102204
Dehydration 68.74 17.32 152 22811 194295 90411189
Impaired gastric emptying 66.27 17.32 41 22922 12768 90592716
Amylase increased 64.95 17.32 33 22930 7039 90598445
Adenocarcinoma pancreas 64.44 17.32 20 22943 1156 90604328
Eructation 61.86 17.32 37 22926 10845 90594639
Treatment failure 61.29 17.32 4 22959 303924 90301560
Wound 61.07 17.32 4 22959 302976 90302508
Nodule 60.89 17.32 52 22911 26634 90578850
Blood triglycerides increased 58.68 17.32 39 22924 13722 90591762
Drug intolerance 57.18 17.32 21 22942 447570 90157914
Pericarditis 56.16 17.32 3 22960 270148 90335336
Pain 54.94 17.32 106 22857 996235 89609249
Musculoskeletal stiffness 54.07 17.32 6 22957 296526 90308958
Device defective 52.87 17.32 23 22940 3463 90602021
Arthropathy 52.45 17.32 14 22949 366228 90239256
Injection site haematoma 51.34 17.32 28 22935 6894 90598590
Product quality issue 50.69 17.32 80 22883 79245 90526239
Rheumatoid arthritis 49.82 17.32 15 22948 362599 90242885
Drug ineffective 48.66 17.32 184 22779 1384114 89221370
Increased appetite 46.95 17.32 32 22931 11733 90593751
General physical health deterioration 46.47 17.32 16 22947 355099 90250385
Product dose omission issue 45.72 17.32 170 22793 291517 90313967
Infection 44.55 17.32 18 22945 362076 90243408
Arthralgia 44.46 17.32 81 22882 778441 89827043
Stomatitis 44.38 17.32 8 22955 274690 90330794
Product use in unapproved indication 44.25 17.32 15 22948 336221 90269263
Pancreatitis necrotising 43.73 17.32 18 22945 2363 90603121
Abdominal pain 43.57 17.32 207 22756 395514 90209970
Hepatic steatosis 43.17 17.32 50 22913 36895 90568589
Helicobacter infection 42.88 17.32 4 22959 226846 90378638
Circumstance or information capable of leading to medication error 42.21 17.32 22 22941 4945 90600539
Pyrexia 42.07 17.32 64 22899 660421 89945063
Nasopharyngitis 41.45 17.32 26 22937 407078 90198406
Injection site swelling 40.53 17.32 62 22901 59777 90545707
Pneumonia 39.51 17.32 63 22900 637996 89967488
Underdose 39.48 17.32 58 22905 53959 90551525
Toxicity to various agents 39.36 17.32 12 22951 287834 90317650
Feeling jittery 39.31 17.32 32 22931 15339 90590145
Peripheral swelling 38.57 17.32 29 22934 413077 90192407
Renal failure 38.17 17.32 95 22868 130912 90474572
Intentional product use issue 38.02 17.32 5 22958 216887 90388597
Neutropenia 37.54 17.32 6 22957 224898 90380586
Impaired healing 37.44 17.32 7 22956 234192 90371292
Hunger 36.49 17.32 22 22941 6541 90598943
Irritable bowel syndrome 35.85 17.32 5 22958 207443 90398041
Alopecia 35.49 17.32 44 22919 495027 90110457
Hepatic enzyme increased 35.41 17.32 24 22939 360712 90244772
Discomfort 34.79 17.32 13 22950 274322 90331162
Drug dose omission by device 34.26 17.32 25 22938 10206 90595278
Injection site abscess 33.70 17.32 13 22950 1441 90604043
Muscle injury 33.69 17.32 3 22960 176651 90428833
Injection site indentation 33.39 17.32 9 22954 314 90605170
Mobility decreased 33.30 17.32 11 22952 250723 90354761
Wheezing 32.41 17.32 10 22953 238070 90367414
Sinusitis 32.13 17.32 24 22939 343064 90262420
Swelling 31.35 17.32 36 22927 419022 90186462
Pancreatitis relapsing 30.82 17.32 12 22951 1364 90604120
Feeling abnormal 30.05 17.32 102 22861 167133 90438351
Injection site inflammation 29.94 17.32 17 22946 4524 90600960
C-reactive protein increased 29.90 17.32 5 22958 181384 90424100
Thyroid cancer 29.71 17.32 19 22944 6265 90599219
Blister 29.26 17.32 14 22949 254984 90350500
Cholecystitis 28.68 17.32 28 22935 17012 90588472
Therapeutic product effect incomplete 28.53 17.32 7 22956 193889 90411595
Confusional state 28.00 17.32 34 22929 386171 90219313
Thrombocytopenia 27.99 17.32 9 22954 208716 90396768
Product quality control issue 27.80 17.32 5 22958 23 90605461
Abdominal distension 27.40 17.32 84 22879 130517 90474967
Injection site induration 27.20 17.32 22 22941 10446 90595038
Urticaria 27.03 17.32 153 22810 312581 90292903
Febrile neutropenia 26.93 17.32 4 22959 158345 90447139
Fatigue 26.84 17.32 177 22786 1153846 89451638
Ill-defined disorder 26.58 17.32 7 22956 184884 90420600
Sleep disorder 25.75 17.32 9 22954 198021 90407463
Medullary thyroid cancer 25.68 17.32 7 22956 255 90605229
Inflammation 25.22 17.32 7 22956 178585 90426899
Hypoglycaemic unconsciousness 25.19 17.32 9 22954 805 90604679
White blood cell count decreased 24.65 17.32 6 22957 167103 90438381
Diabetic neuropathy 24.57 17.32 15 22948 4559 90600925
Injection site warmth 24.41 17.32 26 22937 17489 90587995
Pancreatic duct stenosis 24.34 17.32 5 22958 51 90605433
Medication error 24.24 17.32 61 22902 84591 90520893
Loss of personal independence in daily activities 24.18 17.32 3 22960 136102 90469382
Product use issue 23.96 17.32 29 22934 329890 90275594
Bile duct stent insertion 23.52 17.32 5 22958 61 90605423
Pancreatitis haemorrhagic 23.24 17.32 8 22955 641 90604843
Glycosylated haemoglobin decreased 23.24 17.32 8 22955 641 90604843
Coronary artery disease 22.99 17.32 35 22928 33588 90571896
Product prescribing error 22.94 17.32 33 22930 30112 90575372
Metastases to liver 22.61 17.32 32 22931 28775 90576709
Product dispensing error 22.23 17.32 21 22942 12252 90593232
Intestinal malrotation 22.00 17.32 7 22956 439 90605045
Joint range of motion decreased 21.79 17.32 4 22959 135639 90469845
Injection site infection 21.76 17.32 11 22952 2321 90603163
Therapeutic response unexpected 21.30 17.32 27 22936 21853 90583631
Vomiting projectile 21.29 17.32 10 22953 1799 90603685
Bursitis 20.89 17.32 4 22959 131650 90473834
Glycosylated haemoglobin abnormal 20.89 17.32 6 22957 265 90605219
Type 2 diabetes mellitus 20.63 17.32 13 22950 203231 90402253
Disease progression 20.56 17.32 7 22956 156608 90448876
Nail growth abnormal 19.94 17.32 7 22956 595 90604889
Fibromyalgia 19.85 17.32 14 22949 206255 90399229
Pancreatic neoplasm 19.83 17.32 8 22955 998 90604486
Goitre 19.25 17.32 15 22948 6752 90598732
Lung disorder 19.16 17.32 7 22956 149876 90455608
Drug delivery system issue 19.15 17.32 5 22958 154 90605330
Device failure 19.00 17.32 15 22948 6882 90598602
Dry mouth 18.37 17.32 12 22951 184047 90421437
Night sweats 18.26 17.32 5 22958 128761 90476723
Mass 18.06 17.32 21 22942 15556 90589928
Death 17.71 17.32 58 22905 456493 90148991
Flatulence 17.70 17.32 35 22928 41332 90564152
Myocardial infarction 17.61 17.32 63 22900 105909 90499575
Hypoaesthesia 17.60 17.32 33 22930 314177 90291307

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pancreatitis 1769.32 18.39 655 16006 42613 42562061
Blood glucose increased 1172.14 18.39 571 16090 73128 42531546
Weight decreased 738.07 18.39 624 16037 207324 42397350
Injection site nodule 712.26 18.39 166 16495 1995 42602679
Pancreatitis acute 466.39 18.39 238 16423 33326 42571348
Device leakage 386.69 18.39 147 16514 10138 42594536
Injection site haemorrhage 360.92 18.39 145 16516 11591 42593083
Incorrect dose administered by device 331.88 18.39 95 16566 2661 42602013
Pancreatic carcinoma 311.59 18.39 123 16538 9383 42595291
Injection site mass 274.20 18.39 109 16552 8466 42596208
Nausea 273.15 18.39 524 16137 396275 42208399
Blood glucose decreased 260.79 18.39 122 16539 14097 42590577
Glycosylated haemoglobin increased 249.81 18.39 115 16546 12809 42591865
Wrong technique in device usage process 219.20 18.39 69 16592 2688 42601986
Injection site extravasation 218.88 18.39 71 16590 3051 42601623
Device delivery system issue 205.77 18.39 53 16608 984 42603690
Injection site pain 186.27 18.39 165 16496 57633 42547041
Blood glucose abnormal 165.80 18.39 72 16589 6981 42597693
Cholelithiasis 148.78 18.39 100 16561 23246 42581428
Device malfunction 146.94 18.39 79 16582 12248 42592426
Intentional device misuse 133.57 18.39 29 16632 245 42604429
Pancreatic carcinoma metastatic 132.56 18.39 49 16612 3117 42601557
Lipase increased 110.18 18.39 62 16599 10504 42594170
Hypoglycaemia 108.17 18.39 125 16536 59729 42544945
Device use issue 105.52 18.39 31 16630 952 42603722
Needle issue 95.87 18.39 53 16608 8674 42596000
Drug dose omission by device 94.14 18.39 46 16615 5840 42598834
Product quality issue 93.80 18.39 68 16593 17814 42586860
Injection site pruritus 92.17 18.39 53 16608 9352 42595322
Diabetes mellitus inadequate control 91.08 18.39 63 16598 15327 42589347
Vomiting 79.45 18.39 271 16390 289452 42315222
Adenocarcinoma pancreas 77.11 18.39 27 16634 1467 42603207
Drug delivery system issue 76.90 18.39 15 16646 69 42604605
Device issue 76.90 18.39 54 16607 13455 42591219
Injection site erythema 73.76 18.39 62 16599 20133 42584541
Decreased appetite 71.79 18.39 201 16460 192936 42411738
Blood glucose fluctuation 70.83 18.39 35 16626 4552 42600122
Incorrect dose administered 70.59 18.39 95 16566 52879 42551795
Pancreatitis chronic 69.18 18.39 28 16633 2274 42602400
Underdose 66.79 18.39 54 16607 16612 42588062
Toxicity to various agents 64.93 18.39 7 16654 229129 42375545
Injection site urticaria 58.82 18.39 28 16633 3355 42601319
Injection site bruising 58.56 18.39 43 16618 11482 42593192
Product use in unapproved indication 56.68 18.39 4 16657 184452 42420222
Pancreaticoduodenectomy 55.31 18.39 11 16650 57 42604617
Neutropenia 54.24 18.39 7 16654 199424 42405250
Pancreatitis necrotising 53.84 18.39 27 16634 3622 42601052
Diabetic ketoacidosis 53.12 18.39 54 16607 22313 42582361
Pyrexia 51.59 18.39 47 16614 393995 42210679
Cholecystectomy 49.89 18.39 25 16636 3349 42601325
Metastases to liver 49.32 18.39 45 16616 16281 42588393
Death 46.86 18.39 70 16591 471115 42133559
Injection site irritation 45.78 18.39 19 16642 1645 42603029
Thrombocytopenia 44.44 18.39 10 16651 190269 42414405
Hepatic steatosis 42.45 18.39 47 16614 21401 42583273
Hyperglycaemia 42.01 18.39 69 16592 45790 42558884
Disease progression 41.67 18.39 4 16657 143652 42461022
Renal failure 41.50 18.39 137 16524 143589 42461085
Injection site injury 40.92 18.39 12 16649 366 42604308
Amylase increased 40.87 18.39 28 16633 6701 42597973
Injection site rash 40.08 18.39 26 16635 5686 42598988
Blood triglycerides increased 38.88 18.39 39 16622 15857 42588817
Pneumonia 38.83 18.39 66 16595 422083 42182591
Injury associated with device 38.59 18.39 16 16645 1381 42603293
Anaemia 34.79 18.39 35 16626 280243 42324431
COVID-19 34.23 18.39 3 16658 115945 42488729
Impaired gastric emptying 33.43 18.39 21 16640 4345 42600329
Injection site reaction 32.06 18.39 35 16626 15686 42588988
Malignant neoplasm progression 31.48 18.39 3 16658 108397 42496277
Platelet count decreased 30.94 18.39 8 16653 138573 42466101
Abdominal pain upper 30.62 18.39 86 16575 82523 42522151
Pancytopenia 29.98 18.39 5 16656 117738 42486936
Pancreatic neoplasm 29.79 18.39 12 16649 962 42603712
Pancreatic neuroendocrine tumour 29.61 18.39 9 16652 311 42604363
Condition aggravated 28.59 18.39 36 16625 260718 42343956
Bile duct stent insertion 28.26 18.39 7 16654 110 42604564
Therapeutic product effect decreased 28.18 18.39 53 16608 39097 42565577
Pancreatic stent placement 28.12 18.39 5 16656 12 42604662
General physical health deterioration 28.05 18.39 12 16649 151234 42453440
Biliary dyskinesia 28.03 18.39 6 16655 47 42604627
Drug abuse 27.69 18.39 4 16657 104767 42499907
White blood cell count decreased 27.42 18.39 5 16656 110391 42494283
Pancreatitis haemorrhagic 27.42 18.39 9 16652 401 42604273
Injection site induration 27.27 18.39 17 16644 3470 42601204
Fatigue 27.16 18.39 84 16577 435557 42169117
Abdominal pain 26.25 18.39 145 16516 190326 42414348
Injection site abscess 25.77 18.39 11 16650 1021 42603653
Drug delivery system malfunction 25.65 18.39 9 16652 492 42604182
Drug interaction 25.18 18.39 41 16620 266958 42337716
Early satiety 24.14 18.39 10 16651 861 42603813
Nodule 24.00 18.39 27 16634 12507 42592167
Pancreatic pseudocyst 23.91 18.39 10 16651 882 42603792
Feeling jittery 23.34 18.39 17 16644 4481 42600193
Pancreatic cyst 23.24 18.39 10 16651 947 42603727
Diverticulum 23.19 18.39 21 16640 7520 42597154
Dehydration 23.03 18.39 113 16548 141654 42463020
Hepatic cancer 22.96 18.39 22 16639 8458 42596216
Drug ineffective 22.72 18.39 149 16512 630048 41974626
Eructation 22.45 18.39 18 16643 5468 42599206
Injection site haematoma 21.99 18.39 12 16649 1913 42602761
Hypoglycaemic unconsciousness 21.73 18.39 9 16652 775 42603899
Circumstance or information capable of leading to medication error 21.49 18.39 13 16648 2515 42602159
Diabetic neuropathy 21.08 18.39 16 16645 4486 42600188
Insulin-requiring type 2 diabetes mellitus 21.02 18.39 6 16655 166 42604508
Pancreatic enzymes increased 20.68 18.39 9 16652 876 42603798
Device defective 20.61 18.39 11 16650 1677 42602997
Cholecystitis chronic 20.11 18.39 9 16652 936 42603738
Injection site discomfort 19.78 18.39 12 16649 2334 42602340
Pancreatic duct dilatation 19.55 18.39 5 16656 90 42604584
Leukopenia 19.41 18.39 3 16658 74743 42529931
Therapeutic response unexpected 19.24 18.39 23 16638 11358 42593316
Glycosylated haemoglobin decreased 19.01 18.39 7 16654 440 42604234
Hunger 18.93 18.39 11 16650 1977 42602697
Weight increased 18.92 18.39 88 16573 107895 42496779
Injection site scar 18.92 18.39 7 16654 446 42604228
Pancreatectomy 18.73 18.39 4 16657 31 42604643
Interstitial lung disease 18.55 18.39 4 16657 78458 42526216

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Blood glucose increased 2159.35 18.35 865 22132 131631 110434671
Pancreatitis 1539.78 18.35 616 22381 92917 110473385
Weight decreased 982.74 18.35 795 22202 467262 110099040
Injection site nodule 804.66 18.35 188 22809 4458 110561844
Nausea 639.24 18.35 1008 21989 1234682 109331620
Blood glucose decreased 517.92 18.35 204 22793 29284 110537018
Incorrect dose administered by device 491.11 18.35 137 22860 6677 110559625
Device leakage 478.64 18.35 164 22833 15884 110550418
Injection site haemorrhage 448.42 18.35 190 22807 32838 110533464
Pancreatitis acute 372.84 18.35 202 22795 60072 110506230
Glycosylated haemoglobin increased 364.81 18.35 149 22848 23470 110542832
Device delivery system issue 341.38 18.35 81 22916 2052 110564250
Wrong technique in device usage process 334.56 18.35 102 22895 6799 110559503
Injection site mass 263.97 18.35 120 22877 24493 110541809
Hypoglycaemia 258.35 18.35 205 22792 115899 110450403
Injection site pruritus 257.72 18.35 150 22847 51108 110515194
Injection site pain 241.02 18.35 237 22760 177685 110388617
Device malfunction 219.79 18.35 107 22890 25451 110540851
Vomiting 210.52 18.35 533 22464 910142 109656160
Pancreatic carcinoma 206.56 18.35 87 22910 14785 110551517
Blood glucose abnormal 204.59 18.35 83 22914 12833 110553469
Injection site extravasation 198.45 18.35 76 22921 10093 110556209
Decreased appetite 195.04 18.35 352 22645 475494 110090808
Device use issue 192.27 18.35 58 22939 3726 110562576
Injection site urticaria 187.95 18.35 85 22912 17130 110549172
Incorrect dose administered 153.29 18.35 145 22852 103496 110462806
Needle issue 148.32 18.35 73 22924 17767 110548535
Injection site bruising 143.75 18.35 104 22893 51159 110515143
Injection site erythema 143.57 18.35 134 22863 94042 110472260
Lipase increased 142.23 18.35 72 22925 18600 110547702
Blood glucose fluctuation 137.66 18.35 54 22943 7644 110558658
Diabetic ketoacidosis 124.05 18.35 88 22909 41970 110524332
Drug dose omission by device 119.48 18.35 59 22938 14457 110551845
Injection site rash 116.23 18.35 68 22929 23351 110542951
Injection site irritation 115.05 18.35 42 22955 4882 110561420
Diabetes mellitus inadequate control 110.94 18.35 72 22925 29703 110536599
Acute kidney injury 94.17 18.35 318 22679 635112 109931190
Drug delivery system issue 80.76 18.35 17 22980 244 110566058
Intentional device misuse 78.93 18.35 21 22976 853 110565449
Cholelithiasis 77.50 18.35 80 22917 63342 110502960
Hyperglycaemia 77.48 18.35 92 22905 84998 110481304
Device issue 76.75 18.35 61 22936 34474 110531828
Product quality issue 76.10 18.35 87 22910 77212 110489090
Early satiety 74.20 18.35 24 22973 1939 110564363
Amylase increased 69.20 18.35 39 22958 12480 110553822
Lactic acidosis 67.98 18.35 90 22907 92721 110473581
Eructation 62.42 18.35 38 22959 14019 110552283
Pyrexia 61.32 18.35 58 22939 898207 109668095
Dehydration 59.35 18.35 159 22838 279352 110286950
Injury associated with device 58.68 18.35 25 22972 4364 110561938
Device defective 58.59 18.35 24 22973 3798 110562504
Toxicity to various agents 58.58 18.35 14 22983 480541 110085761
Product use in unapproved indication 56.60 18.35 12 22985 447365 110118937
Feeling jittery 50.94 18.35 34 22963 14688 110551614
Febrile neutropenia 50.75 18.35 4 22993 316763 110249539
Pancreatic carcinoma metastatic 50.05 18.35 22 22975 4142 110562160
Neutropenia 49.58 18.35 9 22988 374611 110191691
Product dose omission issue 49.24 18.35 163 22834 321619 110244683
Pneumonia 48.53 18.35 67 22930 876647 109689655
Injection site indentation 46.18 18.35 11 22986 283 110566019
Treatment failure 45.85 18.35 3 22994 277231 110289071
Impaired gastric emptying 44.35 18.35 30 22967 13245 110553057
Joint swelling 43.22 18.35 19 22978 442826 110123476
Underdose 42.53 18.35 59 22938 63495 110502807
Drug intolerance 42.00 18.35 16 22981 406496 110159806
General physical health deterioration 41.89 18.35 18 22979 425277 110141025
Feeling abnormal 41.60 18.35 106 22891 180605 110385697
Pancreatitis necrotising 41.26 18.35 21 22976 5480 110560822
Injection site induration 41.10 18.35 27 22970 11356 110554946
Thrombocytopenia 40.88 18.35 11 22986 348874 110217428
Blood triglycerides increased 38.27 18.35 35 22962 23891 110542411
Renal failure 36.64 18.35 117 22880 226457 110339845
Musculoskeletal stiffness 36.42 18.35 7 22990 279815 110286487
Device failure 35.95 18.35 21 22976 7186 110559116
Injection site injury 35.71 18.35 12 22985 1092 110565210
Stomatitis 34.67 18.35 7 22990 270235 110296067
Abdominal distension 34.53 18.35 97 22900 175006 110391296
Increased appetite 34.44 18.35 27 22970 14950 110551352
Lower respiratory tract infection 34.03 18.35 5 22992 243101 110323201
Circumstance or information capable of leading to medication error 33.60 18.35 18 22979 5215 110561087
Injection site swelling 33.58 18.35 52 22945 61738 110504564
Rheumatoid arthritis 32.29 18.35 11 22986 299602 110266700
Disease progression 31.98 18.35 6 22991 244028 110322274
Myocardial infarction 31.79 18.35 100 22897 191983 110374319
Glycosylated haemoglobin decreased 30.28 18.35 10 22987 862 110565440
White blood cell count decreased 29.30 18.35 6 22991 229384 110336918
Injection site infection 28.92 18.35 13 22984 2580 110563722
Pain 28.83 18.35 102 22895 954853 109611449
Injection site abscess 28.73 18.35 12 22985 1994 110564308
Intentional product use issue 28.69 18.35 8 22989 247898 110318404
Arthropathy 28.57 18.35 12 22985 287510 110278792
Injection site haematoma 28.35 18.35 16 22981 5130 110561172
Abdominal pain 28.27 18.35 193 22804 512796 110053506
Urticaria 28.11 18.35 136 22861 318721 110247581
Hyperhidrosis 27.83 18.35 94 22903 187204 110379098
Hepatic steatosis 27.81 18.35 42 22955 48789 110517513
Peripheral swelling 27.60 18.35 26 22971 404008 110162294
Adenocarcinoma pancreas 27.34 18.35 12 22985 2251 110564051
C-reactive protein increased 27.22 18.35 6 22991 217913 110348389
Ketoacidosis 27.20 18.35 20 22977 10067 110556235
Coronary artery occlusion 27.06 18.35 24 22973 15748 110550554
Mobility decreased 26.85 18.35 8 22989 237414 110328888
Injection site inflammation 26.74 18.35 15 22982 4756 110561546
Wheezing 26.42 18.35 10 22987 255220 110311082
Drug abuse 26.39 18.35 3 22994 177408 110388894
Therapeutic product effect incomplete 26.31 18.35 7 22990 223798 110342504
Malignant neoplasm progression 25.85 18.35 3 22994 174564 110391738
Therapeutic response unexpected 25.44 18.35 28 22969 23815 110542487
Psoriatic arthropathy 25.43 18.35 5 22992 196756 110369546
Infection 25.10 18.35 23 22974 362177 110204125
Pancreatitis chronic 24.92 18.35 14 22983 4451 110561851
Injection site discomfort 24.01 18.35 16 22981 6891 110559411
Platelet count decreased 23.90 18.35 9 22988 230434 110335868
Confusional state 23.75 18.35 38 22959 468642 110097660
COVID-19 23.13 18.35 11 22986 245049 110321253
Inflammation 22.80 18.35 6 22991 193232 110373070
Anaemia 21.93 18.35 51 22946 547035 110019267
Irritable bowel syndrome 21.59 18.35 4 22993 164211 110402091
Impaired healing 21.57 18.35 7 22990 196710 110369592
Nodule 21.39 18.35 30 22967 32601 110533701
Drug ineffective 21.34 18.35 208 22789 1520332 109045970
Nasopharyngitis 20.91 18.35 31 22966 394330 110171972
Non-cardiac chest pain 20.51 18.35 17 22980 10181 110556121
Sleep disorder 20.20 18.35 8 22989 198636 110367666
Hunger 19.88 18.35 14 22983 6590 110559712
Liver disorder 19.73 18.35 3 22994 142240 110424062
Diverticulum 19.71 18.35 20 22977 15506 110550796
Coronary artery disease 19.64 18.35 45 22952 71645 110494657
Medication error 19.43 18.35 57 22940 105309 110460993
Death 18.89 18.35 78 22919 698791 109867511
Blister 18.86 18.35 12 22985 227364 110338938
Product dispensing error 18.85 18.35 20 22977 16325 110549977
Arthralgia 18.68 18.35 91 22906 779541 109786761

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A10BJ01 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Glucagon-like peptide-1 (GLP-1) analogues
FDA CS M0160181 Glucagon-Like Peptide 1
FDA MoA N0000020058 Glucagon-like Peptide-1 (GLP-1) Agonists
MeSH PA D000097789 Glucagon-Like Peptide-1 Receptor Agonists
MeSH PA D006728 Hormones
MeSH PA D007004 Hypoglycemic Agents
MeSH PA D019440 Anti-Obesity Agents
MeSH PA D054795 Incretins
FDA EPC N0000178480 GLP-1 Receptor Agonist
CHEBI has role CHEBI:35526 hypoglycemic agent
CHEBI has role CHEBI:64088 incretin mimetic
CHEBI has role CHEBI:71196 glucagon-like peptide-1 receptor agonist
CHEBI has role CHEBI:35554 cardiovascular drug
CHEBI has role CHEBI:48407 antiparkinson drug
CHEBI has role CHEBI:74518 anti-obesity agent

Related Drugs by ATC class:

A10BJ Glucagon-like peptide-1 (GLP-1) analogues 5 drugs
albiglutidedulaglutideliraglutidelixisenatidesemaglutide

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Type 2 Diabetes Mellitus Treatment Adjunct indication
Alcoholism contraindication 7200002
Acute vomiting contraindication 23971007
Dehydration contraindication 34095006
Hypertensive disorder contraindication 38341003 DOID:10763
Acute nephropathy contraindication 58574008
Transplant of kidney contraindication 70536003
Pancreatitis contraindication 75694006 DOID:4989
Chronic renal failure syndrome contraindication 90688005
Impaired renal function disorder contraindication 197663003
Gastroparesis contraindication 235675006
Hypoglycemic disorder contraindication 237630007
Calculus in biliary tract contraindication 266474003
Severe diarrhea contraindication 409587002




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.15 acidic
pKa2 3.62 acidic
pKa3 3.86 acidic
pKa4 4.07 acidic
pKa5 4.31 acidic
pKa6 4.6 acidic
pKa7 12.09 acidic
pKa8 12.31 acidic
pKa9 12.61 acidic
pKa10 12.68 acidic
pKa11 12.87 acidic
pKa12 12.92 acidic
pKa13 12.99 acidic
pKa14 13.18 acidic
pKa15 13.2 acidic
pKa16 13.29 acidic
pKa17 13.3 acidic
pKa18 13.4 acidic
pKa19 13.5 acidic
pKa20 13.51 acidic
pKa21 13.52 acidic
pKa22 13.64 acidic
pKa23 13.68 acidic
pKa24 13.77 acidic
pKa25 13.82 acidic
pKa26 13.86 acidic
pKa27 11.25 Basic
pKa28 10.81 Basic
pKa29 10.31 Basic
pKa30 7.86 Basic
pKa31 5.98 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 6515117 Oct. 4, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 6515117 Oct. 4, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 DISCN SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 6515117 Oct. 4, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH BASAL INSULIN OR BASAL INSULIN PLUS METFORMIN
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, A THIAZOLIDINEDIONE, OR COMBINATION OF ANY TWO OF THESE THERAPIES
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH INSULIN ALONE OR INSULIN PLUS ONE OTHER ORAL ANTIDIABETIC MEDICATION
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 IMPROVING GLYCEMIC CONTROL IN PATIENTS 10 YEARS OF AGE AND OLDER WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 REDUCING BODY WEIGHT IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 REDUCING FASTING PLASMA GLUCOSE IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 REDUCING HBA1C IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8906851 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH BASAL INSULIN OR BASAL INSULIN PLUS METFORMIN
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8906851 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8906851 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, A THIAZOLIDINEDIONE, OR COMBINATION OF ANY TWO OF THESE THERAPIES
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8906851 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH INSULIN ALONE OR INSULIN PLUS ONE OTHER ORAL ANTIDIABETIC MEDICATION
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8906851 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8906851 Aug. 18, 2026 IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8906851 Aug. 18, 2026 IMPROVING GLYCEMIC CONTROL IN PATIENTS 10 YEARS OF AGE AND OLDER WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH BASAL INSULIN OR BASAL INSULIN PLUS METFORMIN
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, A THIAZOLIDINEDIONE, OR COMBINATION OF ANY TWO OF THESE THERAPIES
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH INSULIN ALONE OR INSULIN PLUS ONE OTHER ORAL ANTIDIABETIC MEDICATION
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 IMPROVING GLYCEMIC CONTROL IN PATIENTS 10 YEARS OF AGE AND OLDER WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 REDUCING BODY WEIGHT IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 REDUCING FASTING PLASMA GLUCOSE IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 REDUCING HBA1C IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH BASAL INSULIN OR BASAL INSULIN PLUS METFORMIN
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, A THIAZOLIDINEDIONE, OR COMBINATION OF ANY TWO OF THESE THERAPIES
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH INSULIN ALONE OR INSULIN PLUS ONE OTHER ORAL ANTIDIABETIC MEDICATION
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 IMPROVING GLYCEMIC CONTROL IN PATIENTS 10 YEARS OF AGE AND OLDER WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 REDUCING BODY WEIGHT IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 REDUCING FASTING PLASMA GLUCOSE IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 REDUCING HBA1C IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8906851 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH BASAL INSULIN OR BASAL INSULIN PLUS METFORMIN
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8906851 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8906851 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, A THIAZOLIDINEDIONE, OR COMBINATION OF ANY TWO OF THESE THERAPIES
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8906851 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH INSULIN ALONE OR INSULIN PLUS ONE OTHER ORAL ANTIDIABETIC MEDICATION
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8906851 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8906851 Aug. 18, 2026 IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8906851 Aug. 18, 2026 IMPROVING GLYCEMIC CONTROL IN PATIENTS 10 YEARS OF AGE AND OLDER WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH BASAL INSULIN OR BASAL INSULIN PLUS METFORMIN
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, A THIAZOLIDINEDIONE, OR COMBINATION OF ANY TWO OF THESE THERAPIES
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH INSULIN ALONE OR INSULIN PLUS ONE OTHER ORAL ANTIDIABETIC MEDICATION
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 IMPROVING GLYCEMIC CONTROL IN PATIENTS 10 YEARS OF AGE AND OLDER WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 REDUCING BODY WEIGHT IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 REDUCING FASTING PLASMA GLUCOSE IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 REDUCING HBA1C IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 DISCN SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH BASAL INSULIN OR BASAL INSULIN PLUS METFORMIN
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 DISCN SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 DISCN SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, A THIAZOLIDINEDIONE, OR COMBINATION OF ANY TWO OF THESE THERAPIES
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 DISCN SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH INSULIN ALONE OR INSULIN PLUS ONE OTHER ORAL ANTIDIABETIC MEDICATION
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 DISCN SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 DISCN SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 DISCN SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 IMPROVING GLYCEMIC CONTROL IN PATIENTS 10 YEARS OF AGE AND OLDER WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 DISCN SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 REDUCING BODY WEIGHT IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 DISCN SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 REDUCING FASTING PLASMA GLUCOSE IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 DISCN SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 REDUCING HBA1C IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 DISCN SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8906851 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH BASAL INSULIN OR BASAL INSULIN PLUS METFORMIN
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 DISCN SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8906851 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 DISCN SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8906851 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AS ADD-ON TO METFORMIN
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 DISCN SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8906851 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, A THIAZOLIDINEDIONE, OR COMBINATION OF ANY TWO OF THESE THERAPIES
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 DISCN SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8906851 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH INSULIN ALONE OR INSULIN PLUS ONE OTHER ORAL ANTIDIABETIC MEDICATION
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 DISCN SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8906851 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 DISCN SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8906851 Aug. 18, 2026 IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 DISCN SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8906851 Aug. 18, 2026 IMPROVING GLYCEMIC CONTROL IN PATIENTS 10 YEARS OF AGE AND OLDER WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 DISCN SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH BASAL INSULIN OR BASAL INSULIN PLUS METFORMIN
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 DISCN SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 DISCN SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AS ADD-ON TO METFORMIN
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 DISCN SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, A THIAZOLIDINEDIONE, OR COMBINATION OF ANY TWO OF THESE THERAPIES
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 DISCN SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH INSULIN ALONE OR INSULIN PLUS ONE OTHER ORAL ANTIDIABETIC MEDICATION
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 DISCN SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 DISCN SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 DISCN SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 IMPROVING GLYCEMIC CONTROL IN PATIENTS 10 YEARS OF AGE AND OLDER WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 DISCN SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 REDUCING BODY WEIGHT IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 DISCN SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 REDUCING FASTING PLASMA GLUCOSE IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 DISCN SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 REDUCING HBA1C IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8501698 June 20, 2027 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8501698 June 20, 2027 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 DISCN SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8501698 June 20, 2027 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8361972 March 21, 2028 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8361972 March 21, 2028 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 DISCN SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8361972 March 21, 2028 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 DISCN SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8895033 Oct. 4, 2030 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH BASAL INSULIN OR BASAL INSULIN PLUS METFORMIN
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 DISCN SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8895033 Oct. 4, 2030 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AS ADD-ON TO METFORMIN
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 DISCN SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8895033 Oct. 4, 2030 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, A THIAZOLIDINEDIONE, OR COMBINATION OF ANY TWO OF THESE THERAPIES
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 DISCN SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8895033 Oct. 4, 2030 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH INSULIN ALONE OR INSULIN PLUS ONE OTHER ORAL ANTIDIABETIC MEDICATION
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 DISCN SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8895033 Oct. 4, 2030 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 DISCN SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8895033 Oct. 4, 2030 DELAYING GASTRIC EMPTYING IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A PRE-MIXED EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 DISCN SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8895033 Oct. 4, 2030 IMPROVING GLYCEMIC CONTROL IN PATIENTS 10 YEARS OF AGE AND OLDER WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 DISCN SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8895033 Oct. 4, 2030 STIMULATING INSULIN RELEASE IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A PRE-MIXED EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Glucagon-like peptide 1 receptor GPCR AGONIST IC50 9.18 CHEMBL CHEMBL
Glucagon-like peptide 1 receptor GPCR IC50 9.85 CHEMBL

External reference:

IDSource
4024921 VUID
N0000171592 NUI
D04121 KEGG_DRUG
4024921 VANDF
C0167117 UMLSCUI
CHEBI:64073 CHEBI
CHEMBL414357 ChEMBL_ID
D000077270 MESH_DESCRIPTOR_UI
DB01276 DRUGBANK_ID
8219 INN_ID
9P1872D4OL UNII
45588096 PUBCHEM_CID
1242964 RXNORM
110131 MMSL
184698 MMSL
19812 MMSL
d05529 MMSL
010772 NDDF
416859008 SNOMEDCT_US
417734003 SNOMEDCT_US
1135 IUPHAR_LIGAND_ID
9P1872D4OL INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Byetta HUMAN PRESCRIPTION DRUG LABEL 1 0310-6512 INJECTION 250 ug SUBCUTANEOUS NDA 29 sections
Byetta HUMAN PRESCRIPTION DRUG LABEL 1 0310-6524 INJECTION 250 ug SUBCUTANEOUS NDA 29 sections
BYDUREON BCise HUMAN PRESCRIPTION DRUG LABEL 1 0310-6540 INJECTION, SUSPENSION, EXTENDED RELEASE 2 mg SUBCUTANEOUS NDA 29 sections
BYETTA HUMAN PRESCRIPTION DRUG LABEL 1 54868-5384 INJECTION 250 ug SUBCUTANEOUS NDA 30 sections
Exenatide HUMAN PRESCRIPTION DRUG LABEL 1 70121-1685 INJECTION 250 ug SUBCUTANEOUS ANDA 27 sections
Exenatide HUMAN PRESCRIPTION DRUG LABEL 1 70121-1685 INJECTION 250 ug SUBCUTANEOUS ANDA 27 sections
Exenatide HUMAN PRESCRIPTION DRUG LABEL 1 70121-1686 INJECTION 250 ug SUBCUTANEOUS ANDA 27 sections
Exenatide HUMAN PRESCRIPTION DRUG LABEL 1 70121-1686 INJECTION 250 ug SUBCUTANEOUS ANDA 27 sections